Key Points
- Beth Hecht sold 16,667 shares of Xeris on Nov. 11 at an average price of $7.40 for $123,335.80, leaving her with 1,336,843 shares (a 1.23% reduction, valued about $9.89M).
- Analysts are mixed but the consensus is a Moderate Buy with a $9.58 price target, ranging from Oppenheimer’s $18 outperform to Weiss Ratings’ sell.
- Institutional investors own 42.75% of Xeris, with major funds like Vanguard, Goldman Sachs, Qube and Geode recently increasing their stakes.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the company's stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $7.40, for a total value of $123,335.80. Following the completion of the transaction, the insider directly owned 1,336,843 shares of the company's stock, valued at $9,892,638.20. This represents a 1.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Xeris Biopharma Price Performance
NASDAQ XERS traded down $0.01 during trading hours on Friday, reaching $7.25. The company's stock had a trading volume of 497,941 shares, compared to its average volume of 2,516,684. The firm has a fifty day simple moving average of $8.36 and a 200-day simple moving average of $6.46. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.82 and a 52 week high of $10.08. The stock has a market cap of $1.20 billion, a P/E ratio of -72.45 and a beta of 0.21.
Analyst Ratings Changes
Several equities analysts have recently issued reports on XERS shares. Zacks Research downgraded shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 30th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Xeris Biopharma in a research report on Friday, November 7th. Oppenheimer reaffirmed an "outperform" rating and set a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Xeris Biopharma in a research note on Wednesday, October 8th. Finally, Piper Sandler raised their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the stock a "neutral" rating in a research report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.58.
Get Our Latest Research Report on XERS
Institutional Investors Weigh In On Xeris Biopharma
Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Xeris Biopharma by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company's stock worth $44,522,000 after purchasing an additional 210,581 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Xeris Biopharma by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company's stock worth $17,052,000 after buying an additional 244,862 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company's stock valued at $14,429,000 after acquiring an additional 1,245,188 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the period. Finally, Millennium Management LLC lifted its position in shares of Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock valued at $12,726,000 after acquiring an additional 369,420 shares during the period. Institutional investors own 42.75% of the company's stock.
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
